These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 15754530)
21. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Sharp SY; Rogers PM; Kelland LR Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Massari C; Brienza S; Rotarski M; Gastiaburu J; Misset JL; Cupissol D; Alafaci E; Dutertre-Catella H; Bastian G Cancer Chemother Pharmacol; 2000; 45(2):157-64. PubMed ID: 10663631 [TBL] [Abstract][Full Text] [Related]
23. Treatment schedule-dependent effect of 5-fluorouracil and platinum derivatives in colorectal cancer cells. Takara K; Fujita M; Minegaki T; Yamamoto K; Takahashi M; Yokoyama T; Okumura K Eur J Pharm Sci; 2012 Feb; 45(3):272-81. PubMed ID: 22155546 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and toxicodynamics of oxaliplatin in rats: application of a toxicity factor to explain differences in the nephrotoxicity and myelosuppression induced by oxaliplatin and the other platinum antitumor derivatives. Hanada K; Suda M; Kanai N; Ogata H Pharm Res; 2010 Sep; 27(9):1893-9. PubMed ID: 20552253 [TBL] [Abstract][Full Text] [Related]
25. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Zhang S; Lovejoy KS; Shima JE; Lagpacan LL; Shu Y; Lapuk A; Chen Y; Komori T; Gray JW; Chen X; Lippard SJ; Giacomini KM Cancer Res; 2006 Sep; 66(17):8847-57. PubMed ID: 16951202 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Liu J; Kraut E; Bender J; Brooks R; Balcerzak S; Grever M; Stanley H; D'Ambrosio S; Gibson-D'Ambrosio R; Chan KK Cancer Chemother Pharmacol; 2002 May; 49(5):367-74. PubMed ID: 11976830 [TBL] [Abstract][Full Text] [Related]
27. The emerging role of oxaliplatin in the treatment of gastric cancer. Zaniboni A; Meriggi F J Chemother; 2005 Dec; 17(6):656-62. PubMed ID: 16433197 [TBL] [Abstract][Full Text] [Related]
28. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Schmidt W; Chaney SG Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361 [TBL] [Abstract][Full Text] [Related]
29. New platinum agents. A comparison in ovarian cancer. Kelland LR; McKeage MJ Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487 [TBL] [Abstract][Full Text] [Related]
30. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin. Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212 [TBL] [Abstract][Full Text] [Related]
31. The developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum. Cerri S; Piccolini VM; Santin G; Bottone MG; De Pascali SA; Migoni D; Iadarola P; Fanizzi FP; Bernocchi G Neurotoxicol Teratol; 2011; 33(2):273-81. PubMed ID: 20883777 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue. Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402 [TBL] [Abstract][Full Text] [Related]
33. Phase I clinical trial and pharmacokinetics of 4'-carboxyphthalato(1,2-diaminocyclohexane)platinum(II). Kelsen DP; Scher H; Alcock N; Leyland-Jones B; Donner A; Williams L; Greene G; Burchenal JH; Tan C; Philips FS; Young CW Cancer Res; 1982 Nov; 42(11):4831-5. PubMed ID: 7127319 [TBL] [Abstract][Full Text] [Related]
34. [Pharmacological approach to the platinum compounds]. Sasaki Y Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667 [TBL] [Abstract][Full Text] [Related]
35. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Piccart MJ; Lamb H; Vermorken JB Ann Oncol; 2001 Sep; 12(9):1195-203. PubMed ID: 11697824 [TBL] [Abstract][Full Text] [Related]
36. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Martelli L; Di Mario F; Ragazzi E; Apostoli P; Leone R; Perego P; Fumagalli G Biochem Pharmacol; 2006 Sep; 72(6):693-700. PubMed ID: 16844093 [TBL] [Abstract][Full Text] [Related]
37. [Development of carboplatin]. Tsukagoshi S Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318 [TBL] [Abstract][Full Text] [Related]
38. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters? Stojanovska V; McQuade R; Rybalka E; Nurgali K Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002 [TBL] [Abstract][Full Text] [Related]
39. Current status and future prospects for satraplatin, an oral platinum analogue. Choy H; Park C; Yao M Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164 [TBL] [Abstract][Full Text] [Related]
40. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Calvert H; Judson I; van der Vijgh WJ Cancer Surv; 1993; 17():189-217. PubMed ID: 8137341 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]